Marianne P. Allen

Array ( [id] => 16720101 [patent_doc_number] => 20210087248 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-03-25 [patent_title] => MODIFIED FIBROBLAST GROWTH FACTOR 1 (FGF-1) POLYPEPTIDES WITH INCREASED BINDING AFFINITY FOR HEPARIN AND ASSOCIATED METHODS [patent_app_type] => utility [patent_app_number] => 17/010364 [patent_app_country] => US [patent_app_date] => 2020-09-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 5228 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17010364 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19258037 [patent_doc_number] => 12018081 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2024-06-25 [patent_title] => Photoconjugation reactions for modification of specific proteins on live cells [patent_app_type] => utility [patent_app_number] => 17/006635 [patent_app_country] => US [patent_app_date] => 2020-08-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 22 [patent_figures_cnt] => 29 [patent_no_of_words] => 8957 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 22 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17006635 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19210734 [patent_doc_number] => 11999782 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-06-04 [patent_title] => Therapeutic agents for the treatment of diseases associated with undesired cell proliferation [patent_app_type] => utility [patent_app_number] => 17/001530 [patent_app_country] => US [patent_app_date] => 2020-08-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 12 [patent_figures_cnt] => 12 [patent_no_of_words] => 20601 [patent_no_of_claims] => 3 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 38 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17001530 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16620037 [patent_doc_number] => 20210038690 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-02-11 [patent_title] => PROMOTING EPITHELIAL REGENERATION USING HEPARIN BINDING EPIDERMAL GROWTH FACTOR LIKE GROWTH FACTOR [patent_app_type] => utility [patent_app_number] => 16/997607 [patent_app_country] => US [patent_app_date] => 2020-08-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 17083 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16997607 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16628751 [patent_doc_number] => 20210047404 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-02-18 [patent_title] => CD33 ANTIBODIES AND USE OF SAME TO TREAT CANCER [patent_app_type] => utility [patent_app_number] => 16/942647 [patent_app_country] => US [patent_app_date] => 2020-07-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 19062 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -31 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16942647 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16398837 [patent_doc_number] => 20200339695 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-10-29 [patent_title] => SOLUBLE HUMAN ST-2 ANTIBODIES AND ASSAYS [patent_app_type] => utility [patent_app_number] => 16/927168 [patent_app_country] => US [patent_app_date] => 2020-07-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 21116 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -25 [patent_words_short_claim] => 40 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16927168 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16541023 [patent_doc_number] => 20200407436 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-12-31 [patent_title] => ANTAGONIST ANTIBODIES THAT BIND TO HUMAN TGFB1, TGFB2 AND TO TGFB3 AND THEIR USE FOR THE TREATMENT OF LUNG FIBROSIS [patent_app_type] => utility [patent_app_number] => 16/925281 [patent_app_country] => US [patent_app_date] => 2020-07-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 26268 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16925281 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17792144 [patent_doc_number] => 20220251235 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-08-11 [patent_title] => MAGEA10 SPECIFIC T CELL RECEPTORS AND THEIR USE [patent_app_type] => utility [patent_app_number] => 17/625380 [patent_app_country] => US [patent_app_date] => 2020-07-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14037 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -11 [patent_words_short_claim] => 9 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17625380 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16839545 [patent_doc_number] => 20210147557 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-05-20 [patent_title] => ANTI-EGFRVIII ANTIBODIES AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 16/918656 [patent_app_country] => US [patent_app_date] => 2020-07-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 22353 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -24 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16918656 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17990201 [patent_doc_number] => 20220356238 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-11-10 [patent_title] => ANTIBODIES AND ASSAYS FOR CCL14 [patent_app_type] => utility [patent_app_number] => 17/621414 [patent_app_country] => US [patent_app_date] => 2020-07-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 28364 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -40 [patent_words_short_claim] => 57 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17621414 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16584106 [patent_doc_number] => 20210018508 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-01-21 [patent_title] => IGF-1R ANTIBODY AND ITS USE FOR THE DIAGNOSIS OF CANCER [patent_app_type] => utility [patent_app_number] => 16/917376 [patent_app_country] => US [patent_app_date] => 2020-06-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12838 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16917376 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16541022 [patent_doc_number] => 20200407435 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-12-31 [patent_title] => ANTI-ANGPT2 ANTIBODIES [patent_app_type] => utility [patent_app_number] => 16/911419 [patent_app_country] => US [patent_app_date] => 2020-06-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 24131 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -10 [patent_words_short_claim] => 110 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16911419 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16506556 [patent_doc_number] => 20200385812 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-12-10 [patent_title] => FGFR3 FUSION GENE AND PHARMACEUTICAL DRUG TARGETING SAME [patent_app_type] => utility [patent_app_number] => 15/930648 [patent_app_country] => US [patent_app_date] => 2020-05-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 39557 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15930648 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16686829 [patent_doc_number] => 20210069304 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-03-11 [patent_title] => Lysosomal Targeting Peptides and Uses Thereof [patent_app_type] => utility [patent_app_number] => 16/869862 [patent_app_country] => US [patent_app_date] => 2020-05-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16011 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 119 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16869862 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16421931 [patent_doc_number] => 20200347129 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-11-05 [patent_title] => Anti-Marinobufagenin Antibodies and Uses Thereof [patent_app_type] => utility [patent_app_number] => 16/870157 [patent_app_country] => US [patent_app_date] => 2020-05-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 25932 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16870157 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16421941 [patent_doc_number] => 20200347139 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-11-05 [patent_title] => CLEC12a Binding Polypeptides and Uses Thereof [patent_app_type] => utility [patent_app_number] => 16/864481 [patent_app_country] => US [patent_app_date] => 2020-05-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 18899 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -29 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16864481 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16328422 [patent_doc_number] => 20200299388 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-09-24 [patent_title] => EGFR x CD28 MULTISPECIFIC ANTIBODIES [patent_app_type] => utility [patent_app_number] => 16/825179 [patent_app_country] => US [patent_app_date] => 2020-03-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 35374 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -32 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16825179 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16376379 [patent_doc_number] => 20200325221 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-10-15 [patent_title] => TECHNIQUES FOR PREDICTING, DETECTING AND REDUCING ASPECIFIC PROTEIN INTERFERENCE IN ASSAYS INVOLVING IMMUNOGLOBULIN SINGLE VARIABLE DOMAINS [patent_app_type] => utility [patent_app_number] => 16/823412 [patent_app_country] => US [patent_app_date] => 2020-03-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 28394 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16823412 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16156599 [patent_doc_number] => 20200216532 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-07-09 [patent_title] => TECHNIQUES FOR PREDICTING, DETECTING AND REDUCING ASPECIFIC PROTEIN INTERFERENCE IN ASSAYS INVOLVING IMMUNOGLOBULIN SINGLE VARIABLE DOMAINS [patent_app_type] => utility [patent_app_number] => 16/822186 [patent_app_country] => US [patent_app_date] => 2020-03-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 28215 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16822186 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16762394 [patent_doc_number] => 20210107975 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-04-15 [patent_title] => ANTAGONISTS OF IL-6 TO PREVENT OR TREAT CACHEXIA, WEAKNESS, FATIGUE, AND/OR FEVER [patent_app_type] => utility [patent_app_number] => 16/822228 [patent_app_country] => US [patent_app_date] => 2020-03-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 85421 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => 0 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16822228 [rel_patent_id] =>[rel_patent_doc_number] =>)